Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Spruce Biosciences Inc
SPRB | US
62.11
USD6.24
11.17%
SPRB | US
Loading StockChartView...
About Spruce Biosciences Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
09/03/2026
Close
62.11
Open
52.47
High
64.61
Low
52.47
Spruce Biosciences Inc. a biopharmaceutical company focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH) which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research develop and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop manufacture and commercialize tildacerfont for the treatment of CAH in Japan. Spruce Biosciences Inc. was incorporated in 2014 and is headquartered in South San Francisco California.
View LessSPRB | US
Risk
123.1
Sharpe
0.09
Luna's Score
49/100
Recommendation
Hold
Luna says (SPRB | US)
What's Working
Strength based on increasing price with high volume
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
High 6-Month Volatility (>65%)
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
90.4%1 month
123.1%3 months
99.4%6 months
1954.7%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.36
Debt to equity
0.06
Debt to assets
0.05
Ent. to EBITDA
-0.23
Ent. to rev.
15.32
PEG
-
Other Fundamentals
EBITDA
-47.43M
MarketCap
2.57B
MarketCap(USD)
2.57B
Div. yield
-
Op. margin
-623.35
Erngs. growth
-
Rev. growth
-25.60
Ret. on equity
-55.37
Short ratio
0.88
Short perc.
0.92
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
16.11
Range1M
38.87
Range3M
49.16
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.43
Price X volume
4.79M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.23 | 0.53 | Cheaper |
| Ent. to Revenue | 15.32 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.36 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 99.37 | 72.80 | Riskier |
| Debt to Equity | 0.06 | -1.23 | Expensive |
| Debt to Assets | 0.05 | 0.25 | Cheaper |
| Market Cap | 2.57B | 3.66B | Emerging |
